Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice

CompletedOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

June 26, 2012

Primary Completion Date

May 15, 2015

Study Completion Date

May 15, 2015

Conditions
Osteoporosis, Postmenopausal
Interventions
BIOLOGICAL

Denosumab

This is an non-interventional study, therefore denosumab is administered as part of routine care and not for purposes of the study.

Trial Locations (29)

602 00

Research Site, Brno

638 00

Research Site, Brno

370 01

Research Site, České Budějovice

580 22

Research Site, Havlíčkův Brod

367 17

Research Site, Karlovy Vary

284 01

Research Site, Kutná Hora

702 00

Research Site, Ostrava

722 00

Research Site, Ostrava-Trebovice

323 00

Research Site, Pilsen

128 50

Research Site, Prague

148 00

Research Site, Prague

140 00

Research Site, Praha 4 - Nusle

541 21

Research Site, Trutnov

755 01

Research Site, Vsetín

760 01

Research Site, Zlín

Unknown

Osteocentrum Zlin, Zlín

974 01

Research Site, Banská Bystrica

826 06

Research Site, Bratislava

833 05

Research Site, Bratislava

066 01

Research Site, Humenné

040 15

Research Site, Kosice-Saca

040 01

Research Site, Košice

984 01

Research Site, Lučenec

034 91

Research Site, Ľubochňa

036 01

Research Site, Martin

949 01

Research Site, Nitra

080 01

Research Site, Prešov

917 75

Research Site, Trnava

010 01

Research Site, Žilina

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

One Amgen Center Drive

UNKNOWN

collaborator

THOUSAND OAKS

UNKNOWN

collaborator

CA

UNKNOWN

collaborator

91320-1799

UNKNOWN

collaborator

USA

UNKNOWN

lead

Amgen

INDUSTRY

NCT01652690 - Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice | Biotech Hunter | Biotech Hunter